Enrico Colli

Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.

M. Serio, C. Crescioli, S. Gelmini, 2004, European journal of endocrinology.

Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)

C. Crescioli, L. Adorini, A. Morelli, 2006, Journal of endocrinological investigation.